NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic ...

Johnson & Johnson's recent earnings beat expectations, with strong Medicine and MedTech growth. Read why I have a buy rating ...

Some even believe that the new GLP-1 drugs are playing a direct role ... relative to revenues in recent years. Since CapEx is a key component in calculating free cash flow, its increase has ...

While GLP-1 receptor agonists like semaglutide help with weight loss, new research shows users often fall short on vital nutrients, spotlighting the urgent need for tailored dietary guidance.

Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat ... strength training and enough protein were key to keeping muscle while losing weight ...

The adjunctive use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) as an addition to insulin ... In Garg’s own pilot study, a retrospective chart review of 50 patients with T1D and ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Pittsburgh will be entering the series a few games under the .500 mark, and this is a prime opportunity for New York to get some wins. Here are four keys to the series for the Yankees. While there ...

Blockbuster GLP-1 medications like Ozempic and Wegovy are transforming patient care, altering surgery volumes and redefining the healthcare industry’s financial landscape. Beyond weight loss ...